{
    "ticker": "AMRX",
    "name": "Amarin Corporation plc",
    "description": "Amarin Corporation plc is a biopharmaceutical company focused on the development and commercialization of therapeutics to improve cardiovascular health. Founded in 1989, Amarin is headquartered in Dublin, Ireland, and is renowned for its flagship product, Vascepa (icosapent ethyl), which is an FDA-approved prescription medication derived from fish oil. Vascepa is indicated for the reduction of cardiovascular risk in patients with elevated triglyceride levels and has been shown to reduce the risk of heart attacks and strokes. The company's mission is to provide effective therapies that support patient health and improve outcomes in the management of cardiovascular diseases. Amarin is dedicated to advancing clinical research and has conducted extensive studies to demonstrate the safety and efficacy of its products. In addition to Vascepa, Amarin is exploring new indications and formulations to expand its therapeutic offerings and is committed to addressing unmet medical needs in the cardiovascular space. As a leader in cardiovascular therapeutics, Amarin aims to transform the treatment landscape for patients at risk of heart disease through innovative science and a patient-centric approach.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "1989",
    "website": "https://www.amarincorp.com",
    "ceo": "Karim Mikhail",
    "social_media": {
        "twitter": "https://twitter.com/AmarinCorp",
        "linkedin": "https://www.linkedin.com/company/amarin-corporation/"
    },
    "investor_relations": "https://investors.amarincorp.com",
    "key_executives": [
        {
            "name": "Karim Mikhail",
            "position": "CEO"
        },
        {
            "name": "Thomas C. O'Neil",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cardiovascular Therapeutics",
            "products": [
                "Vascepa"
            ]
        }
    ],
    "seo": {
        "meta_title": "Amarin Corporation plc | Cardiovascular Health Solutions",
        "meta_description": "Learn about Amarin Corporation plc, a biopharmaceutical company dedicated to improving cardiovascular health through innovative therapies like Vascepa. Explore our commitment to patient care and cardiovascular research.",
        "keywords": [
            "Amarin",
            "Cardiovascular Health",
            "Vascepa",
            "Biopharmaceuticals",
            "Healthcare",
            "Heart Disease"
        ]
    },
    "faq": [
        {
            "question": "What is Amarin known for?",
            "answer": "Amarin is known for its product Vascepa, a medication used to improve cardiovascular health."
        },
        {
            "question": "Who is the CEO of Amarin?",
            "answer": "Karim Mikhail is the CEO of Amarin Corporation plc."
        },
        {
            "question": "Where is Amarin headquartered?",
            "answer": "Amarin is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are Amarin's main products?",
            "answer": "Amarin's main product is Vascepa, which is used for reducing cardiovascular risk."
        },
        {
            "question": "When was Amarin founded?",
            "answer": "Amarin was founded in 1989."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "REGN",
        "SNY"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}